Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mitobronitol SCHEMBL23128365 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAL3MBTL1TDP1 | |
| Mitobronitol SCHEMBL10047597 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAL3MBTL1TDP1 | |
| Mitobronitol SCHEMBL8456 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAL3MBTL1TDP1 | |
| Mitobronitol SCHEMBL24408845 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAL3MBTL1TDP1 | |
| Mitolactol SCHEMBL8455 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAL3MBTL1TDP1 | |
| SCHEMBL3798965 | 0.87 | ALDH1A1 (0.75) | ALDH1A1LMNAL3MBTL1TDP1 | |
| SCHEMBL8648464 | 0.84 | ALDH1A1 (0.71) | ALDH1A1LMNAL3MBTL1TDP1 | |
| SCHEMBL561011 | 0.82 | — | — | |
| SCHEMBL10837948 | 0.82 | — | — | |
| SCHEMBL4421089 | 0.78 | ALDH1A1 (0.60) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 46329 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748859-A2 | CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF | The Regents of the University of California (US) | 2026-05-27 | — | — | EP | claimed |
| US-20260137650-A1 | MODULATORS OF RAR RELATED ORPHAN RECEPTORS (RORs) | 11949098 CANADA INC (CA) | 2026-05-21 | — | — | US | claimed |
| EP-4743490-A1 | HUMANIZED ANTI-CD7 ANTIBODY | Christian-Albrechts-Universität zu Kiel (DE) | 2026-05-20 | — | — | EP | claimed |
| WO-2026099502-A1 | NOVEL DRUG CONJUGATES FOR TESTING CELLULAR DRUG UPTAKE | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2026-05-15 | — | — | WO | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-20260085100-A1 | METHODS OF ANTIGEN PRODUCTION | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2026-03-26 | — | — | US | claimed |
| US-20260085061-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | SITRYX THERAPEUTICS LIMITED (GB) | 2026-03-26 | — | — | US | claimed |
| EP-4709383-A1 | INVERSE AGONISTS OF RAR RELATED ORPHAN RECEPTORS (RORS) | 11949098 Canada Inc. (CA) | 2026-03-18 | — | — | EP | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| US-12577324-B2 | Antibodies having specificity to HER4 and uses thereof | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2026-03-17 | — | — | US | claimed |
| WO-1999058126-A1 | USE OF NEOMYCIN FOR TREATING ANGIOGENESIS-RELATED DISEASES | THE ENDOWMENT FOR RESEARCH IN HUMAN BIOLOGY, INC. (US) | 1999-11-18 | — | — | WO | claimed |
| WO-1999042578-A2 | MODULATION OF CELL PROLIFERATION, METHODS AND REAGENTS | COLD SPRING HARBOR LABORATORY (US) | 1999-08-26 | — | — | WO | claimed |
| WO-1999025367-A2 | TREATMENT OF HEMATOLOGIC DISORDERS | THE GENERAL HOSPITAL CORPORATION (US) | 1999-05-27 | — | — | WO | claimed |
| WO-1999001118-A9 | ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS | ATHEROGENICS INC (US) | 1999-05-20 | — | — | WO | claimed |
| WO-1999001118-A2 | ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS | ATHEROGENICS, INC. (US) | 1999-01-14 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| WO-1997035569-A1 | USE OF HEME OXYGENASE INHIBITORS TO TREAT CANCER | WILLIAM HARVEY RESEARCH LIMITED (GB) | 1997-10-02 | — | — | WO | claimed |
| EP-0608546-A2 | Glia activating factor (GAF), antibodies against it and their uses | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-08-03 | — | — | EP | claimed |
| EP-0120907-A1 | PHARMACEUTICAL PREPARATIONS FOR USE IN ANTITUMOUR THERAPY | Aston Molecules Limited (GB) | 1984-10-10 | — | — | EP | claimed |
| WO-1984001506-A1 | PHARMACEUTICAL PREPARATIONS FOR USE IN ANTITUMOUR THERAPY | UNIV BIRMINGHAM (GB) | 1984-04-26 | — | — | WO | claimed |